These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review. Găman MA; Cozma MA; Dobrică EC; Crețoiu SM; Găman AM; Diaconu CC Life (Basel); 2021 Jul; 11(7):. PubMed ID: 34357048 [TBL] [Abstract][Full Text] [Related]
12. The Role of Inflammation and Inflammasome in Myeloproliferative Disease. Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883 [TBL] [Abstract][Full Text] [Related]
13. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Michiels JJ; Juvonen E Semin Thromb Hemost; 1997; 23(4):339-47. PubMed ID: 9263350 [TBL] [Abstract][Full Text] [Related]
14. Myeloproliferative Neoplasms in Children. Hofmann I J Hematop; 2015 Sep; 8(3):143-157. PubMed ID: 26609329 [TBL] [Abstract][Full Text] [Related]
15. Recent advances in understanding myelofibrosis and essential thrombocythemia. Vainchenker W; Constantinescu SN; Plo I F1000Res; 2016; 5():. PubMed ID: 27134742 [TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Capello D; Deambrogi C; Rossi D; Lischetti T; Piranda D; Cerri M; Spina V; Rasi S; Gaidano G; Lunghi M Br J Haematol; 2008 May; 141(4):504-11. PubMed ID: 18318760 [TBL] [Abstract][Full Text] [Related]
17. Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000-2018. Mejía-Ochoa M; Acevedo Toro PA; Cardona-Arias JA BMC Cancer; 2019 Jun; 19(1):590. PubMed ID: 31208359 [TBL] [Abstract][Full Text] [Related]
18. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science. Kilpivaara O; Levine RL Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026 [TBL] [Abstract][Full Text] [Related]
19. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable. Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496 [TBL] [Abstract][Full Text] [Related]
20. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases. Chen CQ; Yu K; Yan QX; Xing CY; Chen Y; Yan Z; Shi YF; Zhao KW; Gao SM Carcinogenesis; 2013 Jul; 34(7):1442-9. PubMed ID: 23430957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]